BIO's digital PCR gains and recurring diagnostics base support growth, but a 40.2X forward P/E and muted 2026 outlook keep valuation risk in focus.

Danaher (DHR) is back in focus after its latest trading session, with the stock closing at $211.50. Investors are weighing this move against the company’s recent total return profile and current fundamentals. See our latest analysis for Danaher. The recent 1 day share price return of 5.97% at US$211.50 comes after a mixed stretch, with a 90 day share price return of 22.02% but a year to date share price return that is down 8.20%. The 1 year total shareholder return of 0.79% signals only...

Danaher stock is coming off a mixed five year stretch, with the share price down 23.5%, and the latest checks suggest the shares are not an obvious bargain even though the Discounted Cash Flow (DCF) estimate points to a level close to the current market price. At the same time, traditional market multiples lean on the expensive side, which leaves investors weighing a fairly valued intrinsic estimate against a richer read on earnings based pricing. Over the past five years, Danaher has...

QuidelOrtho's 2026 outlook cut highlights deeper China and respiratory risks, while cash use and rising debt add pressure despite resilient core growth.

QuidelOrtho's resilient core growth and $50 million cost plan offer support, but China weakness, cash use and heavy debt keep the near-term case cautious.

QuidelOrtho's 31.7% three-month rally meets resilient core growth and cost savings, but China weakness, lower guidance and high debt cloud further gains.

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Danaher (NYSE:DHR) and the rest of the research tools & consumables stocks fared in Q2.

Although Danaher has underperformed relative to the broader market over the past year, Wall Street analysts maintain a bullish outlook about the stock’s prospects.

When biopharmaceutical suppliers report earnings, ripples move fast across the sector. On July 21, Danaher Corporation (NYSE:DHR) reported its Q2 2026 results. While the life sciences giant continues to lead in financial scale, its bioprocessing unit missed expectations, signaling continued softness in broader biopharma demand. The news hit European supplier Sartorius AG, which traded lower […]

Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth rates as they’ve already captured significant portions of their markets.

Thermo Fisher Scientific Inc. (NYSE:TMO) and Danaher Corporation (NYSE:DHR) are two of the world’s largest life sciences tools companies, making them natural competitors for investors looking to capitalize on a recovery in pharmaceutical and biotechnology research spending. Both companies delivered better-than-expected second-quarter results, but while Thermo Fisher (NYSE:TMO) raised guidance on broad-based demand improvement, Danaher’s […]

Abbott broadens Diagnostics growth with Exact Sciences, as Cancer Diagnostics gains and resilient routine testing offset respiratory weakness.

Danaher stock now sits around US$194.78 after a weak earnings update and a leadership change on the horizon, and investors are weighing a Discounted Cash Flow (DCF) intrinsic value estimate that points to upside against market multiples that still flag the shares as expensive. Over the past 5 years, Danaher shares have declined about 27.1%, which means long term holders are still under water even before considering valuation. The sharp selloff after the recent earnings miss and the planned...